

# Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates

November 7, 2019

NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – [Predictive Oncology \(NASDAQ: POAI\)](#) announces the availability of a broadcast titled, "New Hope in the Battle Against Ovarian Cancer."

To hear the NetworkNewsWire Audio version, visit: <http://nnw.fm/L4Kxb>

To read the full editorial, visit: <http://nnw.fm/Px2x7>

There's a paradigm shift occurring in cancer therapeutics, and ovarian cancer patients look to be the beneficiaries. Treatment protocols for ovarian cancer have historically consisted of a combination of surgery and chemotherapy. However, the scientific community has come to the realization that, given the vagaries and complexities of a patient's cancer, targeted therapeutics are imperative to increase survival rates. To administer exactly the right drug or drug combinations that give a patient the best chance of survival requires comprehensive molecular information.

That's why the work of [Predictive Oncology \(NASDAQ: POAI\)](#) is so important. Predictive Oncology's subsidiary, Helomics, currently has about 150,000 cases on its molecular information platform, 38,000 of which are specific to ovarian cancer. This unique and valuable scientific asset places Predictive Oncology among the leaders in providing the critical molecular information needed for more effective patient treatments and new drug discovery.

## About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company's data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company's website at [www.Predictive-Oncology.com](http://www.Predictive-Oncology.com).

## About NetworkNewsAudio

[NetworkNewsAudio \(NNA\)](#), a [NetworkNewsWire \(NNW\)](#) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company [AudioPressRelease \(APR\)](#). These audio clips provide snapshots of position, opportunity and momentum. [NetworkNewsAudio \(NNA\)](#) can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. [NetworkNewsWire \(NNW\)](#) is where news, content and information converge. [NetworkNewsWire \(NNW\)](#) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: [www.NetworkNewsAudio.com](http://www.NetworkNewsAudio.com)

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: <http://NNW.fm/Disclaimer>.

## Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

## Corporate Communications:

NetworkWire (NW)  
New York, New York  
[www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)  
212.418.1217 Office  
[Editor@NetworkWire.com](mailto:Editor@NetworkWire.com)

Source: Predictive Oncology